WATCH LIVE
timothy sykes logo
TARS Showcases DexHand AI Robotic Hand, Stock Holds Strong Range Thumbnail
G Google News

TARS Showcases DexHand AI Robotic Hand, Stock Holds Strong Range

JACK KELLOGG•UPDATED JUL. 2, 2026, 5:04 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Tarsus Pharmaceuticals Inc. stocks have been trading up by 10.86 percent following highly positive clinical development news.

Key Takeaways

  • DexHand, an embodied-AI robotic hand from TARS, debuted at the IEEE ICRA 2026 conference.
  • The DexHand platform showed high-fidelity, low-latency hand-brain style control on stage.
  • Conference demos of DexHand drew notable interest from industrial and academic attendees.
  • TARS shares continue to trade in a tight $60–$67 range as traders weigh tech validation against ongoing losses.

Candlestick Chart

Live Update At 17:03:34 EDT: On Thursday, July 02, 2026 Tarsus Pharmaceuticals Inc. stock [NASDAQ: TARS] is trending up by 10.86%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tarsus Pharmaceuticals Inc. (TARS) is trading like a steady grinder, not a meme rocket. Over the recent stretch, TARS has mostly held between about $60 and $67, with the latest close around $65.44 after a bounce from an intraday low near $60.40. That tells traders there’s clear dip-buying interest around the low $60s and some consistent selling or profit-taking closer to the mid‑$60s.

Intraday, TARS showed controlled strength: a morning push off the $60s, then a slow stair-step grind into the high $60s, finishing the day near session highs. That intraday pattern looks like accumulation, not panic.

More Breaking News

On the fundamentals, TARS booked about $162.1M in quarterly revenue and roughly $451.4M on a trailing basis. Gross margin is huge at 93.5%, meaning most revenue drops through after cost of goods. But TARS is still running a net loss of about $7M for the quarter and free cash flow of roughly -$30.5M. Cash stands near $388.7M in cash and short-term investments, and current ratio around 3.7 shows solid liquidity. For traders, TARS is a growth‑mode name: strong top line, heavy spending, still not profitable.

Why Traders Are Watching The DexHand Catalyst

TARS just added a fresh narrative for traders with the DexHand launch. At the IEEE ICRA 2026 conference, the company unveiled its DexHand embodied-AI robotic hand platform, and that matters more than a typical product demo. In front of a high‑end robotics crowd, TARS showed high‑fidelity, low‑latency, hand‑brain style control — the kind of tech language that turns into real‑world contracts if it holds up outside the lab.

The key word here is “validation.” Industrial and academic attendees showed notable interest in DexHand. That means the right people were in the room. When a platform like DexHand catches attention from both industry and academia, TARS gets optionality: research collaborations, pilot programs, and down the road, commercial deals.

For active traders, this is the kind of story that can shift TARS from being seen as just another loss‑making growth name into a potential category leader in embodied AI robotics. The stock’s recent price action — holding mid‑$60s instead of getting sold off — suggests the market is giving TARS the benefit of the doubt on this new tech.

That said, TARS still posts negative EBIT margins and negative returns on equity and assets. Management is clearly choosing to spend on R&D, like DexHand, rather than optimize for near‑term profits. When a company like TARS pairs high gross margins with a visible, buzz‑worthy platform such as DexHand, traders start watching for follow‑through: press releases on partnerships, design wins, or early revenue tied specifically to this AI robotic hand.

Conclusion

TARS now sits at an interesting crossroads. On one side, the numbers show a classic high‑growth, high‑spend profile: strong revenue growth, a 93.5% gross margin, plenty of cash, but negative free cash flow and a string of quarterly losses. On the other side, TARS has a headline‑worthy technology in DexHand that just got a strong reception at IEEE ICRA 2026.

For short‑term traders, TARS around the low‑$60s has been a clear support area. The grind higher into the mid and upper $60s, especially after the DexHand news, shows momentum buyers are active. Range traders are likely mapping $60–$67 as the current battlefield, watching for a volume‑backed breakout or a failed move that cracks support.

Longer‑term, the real question is whether DexHand and similar platforms turn Tarsus Pharmaceuticals Inc. into a consistent cash generator instead of a cash burner. This is exactly where disciplined risk management becomes crucial: as millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.”. Until that answer is visible in the numbers, TARS remains a trading vehicle, not a safe harbor. As Tim Sykes likes to say, “Trade the trends, not the hype — let the chart and the catalyst confirm each other before you size up.” For educational and research-focused traders, TARS now offers both: a clean chart range and a fresh, real catalyst to study.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”